<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551521</url>
  </required_header>
  <id_info>
    <org_study_id>NCT-PMO-1602</org_study_id>
    <nct_id>NCT04551521</nct_id>
  </id_info>
  <brief_title>CRAFT: The NCT-PMO-1602 Phase II Trial</brief_title>
  <official_title>Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whole-genome and transcriptome sequencing of patients with advanced solid tumors enrolled in&#xD;
      the NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program&#xD;
      revealed genetic alterations in a substantial proportion of patients including (i)&#xD;
      alterations that lead to aberrant activation of BRAF, ERBB2, ALK, and the PI3K-AKT and MAPK&#xD;
      pathways and (ii) changes that predict sensitivity to immune checkpoint inhibition, such as&#xD;
      high tumor mutational burden and specific alterations of the PD-L1 locus.&#xD;
&#xD;
      Within this seven-arm basket phase II clinical trial, we aim to investigate the efficacy of&#xD;
      targeted-therapy plus immune checkpoint inhibition in patients with advanced tumors&#xD;
      exhibiting one of the following genetic alterations detected within the NCT/DKTK MASTER&#xD;
      study: (i) BRAF V600E/K, (ii)ERBB2 amplification and/or overexpression or activating ERBB2&#xD;
      mutation, (iii) ALK rearrangement or activating ALK mutation, (iv) activating PIK3CA or AKT&#xD;
      mutations or other aberration predicting increased PI3K-AKT pathway activity, (v) abberations&#xD;
      predicting increased RAF-MEK-ERK pathway activity; (vi) patients with high tumor mutational&#xD;
      burden and/or specific alteration predicting sensitivity to PD-1/PD-L1 inhibition are&#xD;
      eligible within this study for immune checkpoint inhibition. Recruitment of adequate patient&#xD;
      numbers into these well-defined molecular subgroup is achieved in a multicenter approach&#xD;
      including NCT Heidelberg and NCT Dresden as well as DKTK partner sites. Eligible patients&#xD;
      will be identified by in-depth molecular characterization of tumors within the NCT/DKTK&#xD;
      MASTER program. All study arms are based on similar biometrical assumptions, and sample size&#xD;
      as well as power calculations are based on Simon's optimal two-stage design for each study&#xD;
      arm separately. The overall aim is to reduce the cumulative hazard of progression-free&#xD;
      survival observed within the study (PFS2) compared to the cumulative hazard of the&#xD;
      progression-free time before inclusion into the study (PFS1) using a paired log-rank test.&#xD;
      The sample size of the entire trial varies according to the performance of the individual&#xD;
      study arms, ranging between 98 and 175 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Day 110 (+/- 5 days)</time_frame>
    <description>Primary endpoint of the study is to DCR according to RECIST v1.1 including complete response (CR), partial response (PR) and stable disease (SD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months (median)</time_frame>
    <description>Paired Progression-free Survival 2 (PFS2) and Progression-free Survival 1 (PFS1)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Metastatic or Locally Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>BRAF V600E/K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ERBB2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PI3K/AKT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PI3K-AKT-TAX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAPK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune evasion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>960 mg twice daily during run-in Phase, followed by 720 mg twice daily</description>
    <arm_group_label>BRAF V600E/K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>60 mg once daily</description>
    <arm_group_label>BRAF V600E/K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>840 mg every 2 weeks</description>
    <arm_group_label>BRAF V600E/K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks</description>
    <arm_group_label>ERBB2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks</description>
    <arm_group_label>ERBB2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>600 mg twice daily</description>
    <arm_group_label>ALK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>400 mg once daily</description>
    <arm_group_label>PI3K/AKT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>arm 6: 60 mg once daily</description>
    <arm_group_label>MAPK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg every 3 weeks</description>
    <arm_group_label>ERBB2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg in the first cycle, followed by 840 mg every 3 weeks</description>
    <arm_group_label>PI3K/AKT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg in the first cycle, followed by 840 mg every 3 weeks</description>
    <arm_group_label>PI3K-AKT-TAX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipatasertib</intervention_name>
    <description>400 mg once daily, combination with atezolizumab and taxane according to EMA approved indication only</description>
    <arm_group_label>PI3K-AKT-TAX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>840 mg every 2 weeks</description>
    <arm_group_label>MAPK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1,200 mg every 3 weeks</description>
    <arm_group_label>Immune evasion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
          -  Ability of patient to understand and comply with the protocol for the duration of the&#xD;
             study, including treatment and scheduled visits and examinations&#xD;
&#xD;
          -  Diagnosis of a metastatic or locally advanced malignancy&#xD;
&#xD;
          -  Progressive disease&#xD;
&#xD;
          -  At least one measurable lesion that can be accurately assessed at baseline by computed&#xD;
             tomography or magnetic resonance imaging and is suitable for repeated assessment&#xD;
&#xD;
          -  Prior administration of at least one standard chemotherapy for primary and/or relapsed&#xD;
             malignancy according to current guidelines&#xD;
&#xD;
          -  ECOG Performance Status ≤2&#xD;
&#xD;
          -  Age ≥18 years, no upper age limit&#xD;
&#xD;
          -  Postmenopausal or evidence of non-childbearing status.&#xD;
&#xD;
          -  Female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential who are sexually active must agree to the use of two highly&#xD;
             effective forms of contraception. These should be started immediately after signing&#xD;
             the informed consent form and continued throughout the period of study treatment plus&#xD;
             three months for female and for male patients thereafter.&#xD;
&#xD;
          -  Availibility of complete information about the last medical treatment given before&#xD;
             study participation, i.e. remission status before start of treatment, dosage and&#xD;
             timing of drugs applicated, remission status and date of progression after treatment&#xD;
             (in order to calculate PFS 1)&#xD;
&#xD;
          -  For patients included on the basis of molecular testing other than NCT/DKTK MASTER and&#xD;
             for patients with an analysis in NCT/DKTK MASTER performed more than 3 months (date of&#xD;
             tissue sampling) before planned study inclusion, a new tumor biopsy before start of&#xD;
             study treatment is mandatory. However, patients may be included in the trial with&#xD;
             archival tissue not older than 3 months on the basis of a case by case discussion with&#xD;
             the PI.&#xD;
&#xD;
        Arm-specific Inclusion Criteria as determined by Whole Genome Sequencing and RNA Sequencing&#xD;
        in NCT/DKTK MASTER or identification by gene panel performed in a certified lab Eligibility&#xD;
        for the trial and the respective trial arms will be evaluated and determined exclusively by&#xD;
        the NCT/DKTK molecular tumor board on the basis of results from NCT/DKTK MASTER (for all&#xD;
        arms) or of results from other molecular studies, e.g. gene panel testing, performed in a&#xD;
        certified laboratory (for arms 1-6). Trial participation is only possible with a report of&#xD;
        the NCT/DKTK MASTER MTB confirming trial eligibility.&#xD;
&#xD;
          -  Arm 1 (BRAF V600E/K): BRAF V600E/K mutation&#xD;
&#xD;
          -  Arm 2 (ERBB2): ERBB2 amplification/overexpression, activating ERBB2 mutation&#xD;
&#xD;
          -  Arm 3 (ALK): ALK rearrangement or activating ALK mutations including alternative&#xD;
             transcription initiation (ALK-ATI) or RET-fusions&#xD;
&#xD;
          -  Arm 4 (PI3K-AKT): Activating PIK3CA or AKT mutations; other aberrations predicting&#xD;
             increased PI3K-AKT pathway activity, e.g. PTEN loss&#xD;
&#xD;
          -  Arm 5: (PI3K-AKT-TAX): Activating PIK3CA or AKT mutations; other aberrations&#xD;
             predicting increased PI3K-AKT pathway activity, e.g. PTEN lossa&#xD;
&#xD;
          -  Arm 6 (MAPK): Aberrations other than BRAF V600E/K predicting increased RAF-MEK- ERK&#xD;
             pathway activity&#xD;
&#xD;
          -  Arm 7 (Immune evasion): High tumor mutational burden and/or specific alterations&#xD;
             predicting sensitivity to PD1/PDL1 inhibition (e.g. DNA mismatch repair deficiency or&#xD;
             PDL1 amplification and/or overexpression), ineligibility for the six specific arms&#xD;
&#xD;
        Exclusion Criteria (general):&#xD;
&#xD;
          -  Other malignancy except for study indication within the last 5 years except:&#xD;
             adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the&#xD;
             cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or&#xD;
             other malignancies curatively treated with no evidence of disease for ≥5 years&#xD;
&#xD;
          -  Concurrent or previous treatment within 30 days prior to C1D1 in another&#xD;
             interventional clinical trial with an investigational anticancer therapy&#xD;
&#xD;
          -  Persistent toxicity (≥Grade 2 according to Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) version 5.0) caused by previous cancer therapy, excluding alopecia&#xD;
&#xD;
          -  Clinical signs of active infection (&gt;Grade 2 according to CTCAE version 5.0)&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection and immunocompromised patients&#xD;
&#xD;
          -  Active Hepatitis A virus infection&#xD;
&#xD;
          -  Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B&#xD;
             surface antigen (HBsAg) test at baseline patients with a past or resolved HBV&#xD;
             infection, defined as having a negative HBsAg test and a positive total hepatitis B&#xD;
             core antibody (HBcAb) test at baseline , are eligible for the study if active HBV&#xD;
             infection is ruled out on the basis of HBV DNA viral load per local guidelines&#xD;
&#xD;
          -  Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody&#xD;
             test at baseline confirmed by a polymerase chain reaction (PCR) positive for HCV RNA&#xD;
             Dementia or significant impairment of cognitive state&#xD;
&#xD;
          -  Epilepsy requiring pharmacologic treatment&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Inability to take oral medication orgastrointestinal disorders likely to interfere&#xD;
             with absorption of the study medication&#xD;
&#xD;
          -  Major surgery within four weeks of starting study treatment&#xD;
&#xD;
          -  Systemic chemotherapy or radiotherapy within two weeks prior to start of study&#xD;
             treatment or a longer period depending on the characteristics of the agents used (at&#xD;
             least five-half lives)&#xD;
&#xD;
          -  Heart failure New York Heart Association (NYHA) II/III/IV&#xD;
&#xD;
          -  Severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
          -  Prior allogeneic bone marrow transplantation or solid organ transplant.&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before initiation of study&#xD;
             treatment or anticipation that such a live attenuated vaccine will be required during&#xD;
             the study&#xD;
&#xD;
          -  Patients with clinical suspicion of active tuberculosis&#xD;
&#xD;
          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug&#xD;
&#xD;
          -  Is taking or requiring the continued use of any of the prohibited concomitant&#xD;
             medications listed in 5.10&#xD;
&#xD;
          -  Any concurrent antineoplastic therapy.&#xD;
&#xD;
          -  Known suspected active alcohol or drug abuse&#xD;
&#xD;
          -  Hematological malignancies and primary brain tumors. Patients with known progressive&#xD;
             brain metastases determined by serial imaging or declining neurologic function in the&#xD;
             opinion of the treating physician are not eligible. Patients with symptomatic&#xD;
             uncontrolled brain metastases and patients with symptomatic uncontrolled spinal cord&#xD;
             compression are not eligible. Patients with previously treated brain metastases are&#xD;
             eligible, provided that the patient has not experienced a seizure or had a clinically&#xD;
             significant change in neurological status within the three months prior to enrollment.&#xD;
             All patients with previously treated brain metastases must be clinically stable for at&#xD;
             least 1 month after completion of treatment and off steroid treatment for one month,&#xD;
             both prior to study enrolment. Patients with asymptomatic untreated CNS disease may be&#xD;
             enrolled, provided all of the following criteria are met:&#xD;
&#xD;
               -  Evaluable or measurable disease outside the CNS&#xD;
&#xD;
               -  No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm&#xD;
                  of the optic apparatus (optic nerves and chiasm)&#xD;
&#xD;
               -  No history of intracranial hemorrhage or spinal cord haemorrhage&#xD;
&#xD;
               -  No ongoing requirement for dexamethasone for CNS disease; patients on a stable&#xD;
                  dose of anticonvulsants are permitted&#xD;
&#xD;
          -  Immune disease as specified below (relevant for all patients at Baseline except arm 3&#xD;
             (Alectinib))&#xD;
&#xD;
               -  History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
                  myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid&#xD;
                  arthritis, inflammatory bowel disease, vascular thrombosis associated with&#xD;
                  antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome,&#xD;
                  Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis;&#xD;
                  autoimmune-related hypothyroidism (patients on a stable dose of thyroid&#xD;
                  replacement hormone are eligible for this study) and type I diabetes mellitus&#xD;
                  (patients on a stable dose of insulin regimen are eligible for this study).&#xD;
&#xD;
               -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g.,&#xD;
                  bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or&#xD;
                  active pneumonitis; history of radiation pneumonitis in the radiation field&#xD;
                  (fibrosis) is permitted.&#xD;
&#xD;
               -  Psoriatic arthritis (however, patients with eczema, psoriasis, lichen simplex&#xD;
                  chronicus, or vitiligo with dermatologic manifestations only are permitted&#xD;
                  provided that they meet the following conditions:&#xD;
&#xD;
               -  Rash must cover less than 10% of body surface area (BSA)&#xD;
&#xD;
               -  Disease is well controlled at baseline and only requiring low potency topical&#xD;
                  steroids&#xD;
&#xD;
               -  No acute exacerbations of underlying condition within the previous 12 months (not&#xD;
                  requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids,&#xD;
                  biologic agents, oral calcineurin inhibitors, high potency or oral steroids]).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Schlenk, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>NCT Studienzentrale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Schlenk, Prof. Dr.</last_name>
    <phone>+49622156</phone>
    <phone_ext>6228</phone_ext>
    <email>richard.schlenk@nct-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Fröhling, Prof. Dr.</last_name>
    <phone>06221 56</phone>
    <phone_ext>35212</phone_ext>
    <email>stefan.froehling@nct-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Ochsenreither, PD Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT)</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Heining, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard F. Schlenk, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg- Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Desuki, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

